Momentum: MACD histogram is negative (-0.0281) and negatively expanding → bearish momentum strengthening.
RSI (6): 42.57 (neutral-to-weak), not showing oversold conditions that would support a strong reversal buy.
Levels: Price 2.01 is below the pivot (2.944) and closer to support S1 (1.851); a break below S1 increases downside risk toward S2 (1.176). Resistance overhead at 2.944 then 4.036.
Pattern-based outlook (provided): only small expected gains over next day/week/month (sub-1%), not compelling versus technical risk.
Price is showing a strong one-day upside move (+8.7%), which could attract short-term momentum traders.
Hedge fund and insider trading trends are neutral (no notable recent selling pressure flagged in the provided trends).
Neutral/Negative Catalysts
creates near-term breakdown risk if momentum fades.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 0 (no growth base; effectively no operating revenue).
Net income: -1,691,989 (worse YoY; down -46.68% YoY per snapshot).
EPS: -1.65 (deteriorated sharply; down -91.92% YoY).
Overall: continued loss-making profile with no top-line traction shown in the provided snapshot.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating changes or price target updates were provided, so the recent Wall Street trend can’t be confirmed from this dataset.
Practical read-through from available data: absent coverage/catalysts plus weak financials typically keeps institutional/analyst enthusiasm limited, which is a headwind for sustained upside.
Wall Street analysts forecast DRMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRMA is 10 USD with a low forecast of 10 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast DRMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRMA is 10 USD with a low forecast of 10 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.770
Low
10
Averages
10
High
10
Current: 1.770
Low
10
Averages
10
High
10
Maxim
Buy
downgrade
$30 -> $10
AI Analysis
2025-08-21
Reason
Maxim
Price Target
$30 -> $10
AI Analysis
2025-08-21
downgrade
Buy
Reason
Maxim lowered the firm's price target on Dermata Therapeutics to $10 from $30 and keeps a Buy rating on the shares. The company's Q2 results saw operating expenses below the firm's estimate and GAAP loss per share narrower than its estimate, though Maxim is cutting its price target to reflect the share dilution from an anticipated capital raise, the analyst tells investors in a research note.
Maxim
Anthony Vendetti
Buy
downgrade
$6 -> $3
2025-05-21
Reason
Maxim
Anthony Vendetti
Price Target
$6 -> $3
2025-05-21
downgrade
Buy
Reason
Maxim analyst Anthony Vendetti lowered the firm's price target on Dermata Therapeutics to $3 from $6 and keeps a Buy rating on the shares. The firm notes the company's Q1 operating expenses were below its estimates while also citing its statistically significant positive topline data from STAR-1 study, though its adjusted model reflects Dermata's anticipated capital raise, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DRMA
